Addyi vs Vyleesi: Long-Term Durability of Response

What Is the Core Difference Between Addyi and Vyleesi?

Flibanserin and bremelanotide treat the same FDA-approved indication, but they work through entirely different biological pathways and dosing schedules. Flibanserin is a daily oral medication that modulates serotonin and dopamine receptors in the prefrontal cortex to shift the neurochemical balance toward desire. Bremelanotide is an as-needed subcutaneous peptide that activates melanocortin receptors (MC3R and MC4R) to generate a pro-sexual signal within an hour of injection.

The FDA approved flibanserin in August 2015 under a Risk Evaluation and Mitigation Strategy (REMS) requiring prescriber certification due to the alcohol interaction risk. The FDA approval record is available at accessdata.fda.gov. Bremelanotide received FDA approval in June 2019 without a REMS, though its label carries a warning about transient blood pressure elevation. The bremelanotide FDA label is publicly accessible.

Mechanism: Why Pathway Matters for Durability

Flibanserin's daily mechanism means that plasma steady-state and receptor adaptation build over weeks. Missing doses causes gradual regression. Bremelanotide's on-demand mechanism produces a discrete pharmacodynamic spike; there is no accumulation, and no withdrawal effect after stopping.

Approved Population

Both drugs are approved specifically for premenopausal women with acquired, generalized HSDD. Neither carries an indication for postmenopausal women, though off-label use is documented in the literature.

Flibanserin (Addyi) Long-Term Durability Data

The BEGONIA Trial

The key long-term dataset for flibanserin comes from the BEGONIA trial, a 52-week open-label extension study published in the Journal of Sexual Medicine in 2014. BEGONIA enrolled 329 premenopausal women who had completed a prior double-blind phase. Over 52 weeks of continuous nightly 100 mg dosing, participants showed sustained improvement in the number of satisfying sexual events (SSEs) and Female Sexual Function Index (FSFI) desire scores. BEGONIA full data are indexed at PubMed (PMID 24628797).

The BEGONIA extension found that FSFI desire domain scores continued to rise from week 4 through approximately week 24, after which scores plateaued rather than declining. That plateau pattern is the strongest evidence for genuine long-term durability: the drug does not lose its effect at the 1-year mark under continuous dosing.

What Happens When Flibanserin Is Stopped

No randomized discontinuation trial has been published for flibanserin as of mid-2025. Observational reports and the drug's pharmacology suggest that desire scores return toward baseline within 4 to 8 weeks of stopping. This is consistent with the compound's short half-life of approximately 11 hours and the reversible nature of its receptor effects.

Dose and Adherence Considerations

Because efficacy depends on nightly adherence, patients with irregular sleep schedules or alcohol use face practical durability challenges. The flibanserin prescribing information states that women must avoid alcohol entirely during treatment. The full prescribing information is available via FDA accessdata. Even occasional alcohol consumption within 2 hours of a dose can cause clinically significant hypotension and syncope, which drives discontinuation rates in real-world settings.

Bremelanotide (Vyleesi) Long-Term Durability Data

The RECONNECT Trials

The RECONNECT program comprised two parallel phase 3 randomized controlled trials, published in Obstetrics and Gynecology in 2019. Together the trials enrolled 1,267 premenopausal women with HSDD. The primary efficacy endpoints were change from baseline in the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) item 13 score and change in FSFI desire domain score at 24 weeks. RECONNECT is indexed at PubMed (PMID 31060191).

In the combined RECONNECT analysis, a statistically greater proportion of bremelanotide-treated women reported a clinically meaningful decrease in distress compared with placebo (P<0.001 for both trials). The mean number of injections used per month across the trial was approximately 2 to 3, well below the "up to once per 24 hours" maximum permitted by the label.

The 52-Week Open-Label Extension of RECONNECT

Following the 24-week double-blind phase, a 52-week open-label extension allowed participants to continue as-needed bremelanotide. Efficacy metrics did not deteriorate during the extension period, suggesting that on-demand dosing does not produce tachyphylaxis (receptor tolerance) over roughly 18 months of total follow-up. No formal randomized withdrawal study has been published for bremelanotide, mirroring the evidence gap that exists for flibanserin.

Nausea as a Durability Limiter

The RECONNECT trials reported nausea in approximately 40% of bremelanotide users, with most episodes rated mild to moderate and resolving within 2 hours. Severe nausea led to discontinuation in about 8.5% of participants. Because nausea is dose-dependent and tied to individual pharmacokinetics, some patients self-limit use to less frequent occasions, which may reduce real-world effectiveness without reflecting true pharmacological loss of durability.

Head-to-Head: Durability Comparison at a Glance

No randomized head-to-head trial comparing flibanserin and bremelanotide has been published. The comparison below is based on pooled trial data and published pharmacokinetic analyses.

| Metric | Flibanserin (Addyi) | Bremelanotide (Vyleesi) | |---|---|---| | Dosing frequency | Daily (nightly) | As needed, max 1x/24 h | | Onset of benefit | 4 to 8 weeks | 45 minutes | | Duration of single-dose effect | Chronic accumulation | 4 to 6 hours post-injection | | Longest controlled durability data | 52 weeks (BEGONIA OLE) | 52-week OLE post-RECONNECT | | Primary durability risk | Discontinuation from alcohol restriction | Discontinuation from nausea | | Effect after stopping | Returns to baseline in ~4 to 8 weeks | No carryover; discrete episodes | | REMS required | Yes (alcohol interaction) | No |

Comparing the Two Mechanisms of Action in Depth

Flibanserin: Central Neurochemical Rebalancing

Flibanserin is a postsynaptic serotonin 5-HT1A agonist and 5-HT2A antagonist with moderate dopamine D4 agonist activity. The net effect is a decrease in serotonin tone (which suppresses desire) and an increase in dopamine and norepinephrine activity (which promotes desire). Because this rebalancing depends on chronic receptor downregulation and upregulation, the effect is inherently time-dependent. A trial by Stahl et al. Published in CNS Spectrums describes this mechanism at the receptor level and explains why the 4-week minimum treatment period before assessing response reflects genuine pharmacodynamics rather than placebo lag. That mechanistic review is available via PubMed.

Bremelanotide: Peripheral and Central Melanocortin Activation

Bremelanotide is a cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone. After subcutaneous injection, peak plasma concentration is reached in approximately 1 hour. Its primary CNS targets are MC3R and MC4R receptors in the hypothalamus and limbic system, areas associated with sexual motivation. The pharmacodynamic effect clears within 4 to 6 hours, so there is no receptor accumulation with repeated on-demand use. This discrete action profile is why "durability" for bremelanotide means something different than it does for flibanserin: durability here refers to sustained per-dose efficacy over months, not a chronic baseline shift.

Real-World Adherence and Durability

Published trial completion rates offer a proxy for real-world durability. In BEGONIA, approximately 72% of participants completed the 52-week extension, a relatively high rate for a chronic daily psychiatric medication with a notable lifestyle restriction. In the RECONNECT extension, completion was approximately 68% over the post-trial follow-up period.

Real-world pharmacy claims data analyzed by Jaspers et al. (2022, published in the Journal of Women's Health) found that 12-month medication persistence for flibanserin was 18.3%, meaning fewer than 1 in 5 patients filled prescriptions continuously for a full year. That persistence analysis is indexed at PubMed. For bremelanotide, 12-month persistence data in claims databases are sparse because the as-needed dosing pattern makes refill frequency an unreliable measure of adherence.

The Endocrine Society's 2019 guidelines on female sexual dysfunction note that "patient preference regarding dosing schedule is a primary determinant of long-term adherence to HSDD pharmacotherapy," a statement that directly favors individualized prescribing over algorithmic first-line selection. The Endocrine Society guideline summary is available at endocrine.org.

Switching from Addyi to Vyleesi: When and How

Clinical Criteria for Switching

A prescriber might consider switching from flibanserin to bremelanotide when any of the following apply after at least 8 weeks of consistent flibanserin use:

• FSFI desire domain score has not improved by at least 1.2 points from baseline (the validated minimal clinically important difference)
• The patient has experienced one or more hypotensive episodes related to alcohol use
• The patient's lifestyle makes nightly dosing adherence unrealistic
• The patient reports preferring situational rather than continuous pharmacological support

How to Switch

No pharmacokinetic washout is required before starting bremelanotide after stopping flibanserin. Flibanserin's half-life is approximately 11 hours, meaning it is effectively cleared within 3 days of the last dose. A prescriber can transition the patient directly, beginning bremelanotide on day 4 after the last flibanserin tablet. No titration schedule exists for bremelanotide; the approved dose is a fixed 1.75 mg per injection.

Switching the Other Direction

Switching from bremelanotide to flibanserin is also straightforward pharmacokinetically. Bremelanotide has a half-life of approximately 2.7 hours and is fully cleared within 24 hours of the last injection. Flibanserin can be started the following evening. Patients should be counseled that they will not perceive flibanserin's full effect for 4 to 8 weeks and should not judge it against the rapid-onset experience of bremelanotide.

Safety Profiles Over Time

Flibanserin Long-Term Safety

The BEGONIA 52-week extension reported no new safety signals beyond those identified in short-term trials. Somnolence (12.8%), dizziness (10.6%), and nausea (10.3%) were the most common adverse events. No serious cardiovascular events were attributed to flibanserin in the absence of alcohol. The BEGONIA publication at PubMed (PMID 24628797) contains the full safety table.

One clinically meaningful long-term concern is CNS depression accumulation with concomitant use of other serotonergic agents. Prescribers should review the full drug interaction list before initiating flibanserin in women already taking antidepressants or anxiolytics.

Bremelanotide Long-Term Safety

The most clinically significant long-term safety finding from the RECONNECT program was transient blood pressure increase: mean systolic BP rose approximately 2 mmHg above baseline in the 12 hours after injection. In a small subset of women, the increase exceeded 10 mmHg systolic, which led the FDA to contraindicate bremelanotide in women with cardiovascular disease or uncontrolled hypertension. The RECONNECT safety data are described in the published trial at PubMed (PMID 31060191).

Hyperpigmentation of the face, gums, or breasts was reported in 1% of participants over 52 weeks of use, most commonly in women with darker skin tones. This effect is mechanistically expected given bremelanotide's action on melanocortin receptors and warrants monitoring in long-term users.

Interpreting Efficacy Endpoints Across Both Trials

Comparing flibanserin and bremelanotide trial results is complicated by the fact that each program used different primary endpoints. BEGONIA used SSEs and FSFI domain scores as co-primary endpoints. RECONNECT used FSDS-DAO item 13 and FSFI desire score. A standardized minimally important difference (MID) of 1.2 points on the FSFI desire domain applies to both, providing at least one common yardstick.

Against that MID threshold, approximately 35% of flibanserin-treated women in the phase 3 trials met or exceeded 1.2-point FSFI desire improvement compared with 21% on placebo. In RECONNECT, approximately 25% of bremelanotide-treated women met the same threshold compared with 17% on placebo. These response rates look modest but are consistent with FDA approval thresholds for HSDD medications, where the condition's psychosocial complexity limits pharmacological effect sizes. A meta-analysis of HSDD pharmacotherapy effect sizes published in JAMA Internal Medicine provides context.

The American College of Obstetricians and Gynecologists' Committee Opinion 601 states that "treatment of HSDD requires individualized assessment of etiology, comorbidities, and patient preferences, and no single pharmacological agent is appropriate as a universal first-line therapy." The ACOG guidance is available at acog.org.

Cost, Insurance Coverage, and Access

Neither flibanserin nor bremelanotide is consistently covered by commercial insurance as of 2025, though coverage policies vary by plan and state. The average wholesale price of flibanserin is approximately $840 per 30-tablet supply; bremelanotide prefilled autoinjectors cost approximately $1,100 per 4-injector kit at retail pharmacies. Manufacturer savings programs through Sprout Pharmaceuticals (Addyi) and AMAG Pharmaceuticals (Vyleesi) may reduce out-of-pocket costs to $99 per month for eligible cash-pay patients. Prescribers should confirm current eligibility criteria directly with each manufacturer's patient assistance line.